Dengue vaccine expected to be available within three to five years

Singapore: Singapore media reported on the 6th that the dengue vaccine is expected to be available in three to five yearsJean SexoUk, president of the multinational pharmaceutical company GlaxoSmithKline, said the company's chief executive, Jean-ShisleCh, was the firm of the United Morning PostStephanie said in an interview Friday that the company is working on 25 new vaccines, one of which is dengue feverGlaxoSmithKline began developing a dengue vaccine ten years agoPhase II clinical testing has recently begun in Thailand, and the company plans to conduct clinical trials in Latin AmericaThe initial test results for the dengue vaccine are quite satisfactoryClinical testing will take several years to prove that vaccines are safe for people of all agesGlaxoSmithKline's dengue vaccine is a combination of ingredients that fight four dengue viruses, and vaccinators estimate they must be given two dosesStephanie says research on the dengue vaccine is challengingThe main reason is that there are four types of dengue virus, and the vaccine must suppress four different viruses at the same timeIf the vaccine does not suppress one of these types of virus, the vaccinated person happens to be infected with the virus, and the vaccine can worsen the conditionStephanie points out that the process for producing dengue vaccines is also complexThe dengue vaccine is made up of four vaccines, which means there must be four production linesIn addition to GlaxoSmithKline, French pharmaceutical company Sanofi-Avant and Swiss drugmaker Novati are also developing a dengue vaccineDengue fever in Singapore returned to the highest level last week, with 381 cases a weekDengue outbreaks have also occurred in other Southeast Asian countriesIn May alone, 3,650 people were infected with dengue fever in Thailand